Fauna Bio Inc. has identified 5-HT3 receptor antagonists reported to be useful for the treatment of cardiovascular and respiratory disorders.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Beijing Double-Crane Runchuang Technology Co. Ltd. has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Kallyope has divulged compounds acting as tachykinin NK3 receptor antagonists reported to be useful for the treatment of migraine.

Alphina Therapeutics Inc. has described nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors reported to be useful for the treatment of cancer, and autoimmune, inflammatory and metabolic disorders.

Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of heart failure, chronic kidney disease, acute kidney injury, fibrosis and inflammatory disorders.

Iambic Therapeutics Inc. has synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Blueprint Medicines Corp. has disclosed EGFR mutant inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).

GW Research Ltd. has described cannabinoid compounds reported to be useful for the treatment of epilepsy and seizures.

Nippon Shinyaku Co. Ltd. has divulged azaindole compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, rheumatoid arthritis, psoriasis, spinal cord injury, Behçet’s disease, atopic dermatitis and idiopathic pulmonary fibrosis, among others.